Roth MKM Maintains Buy on BioRestorative Therapies, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jonathan Aschoff maintains a Buy rating on BioRestorative Therapies (NASDAQ:BRTX) and raises the price target from $15 to $18.
August 14, 2024 | 2:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roth MKM analyst Jonathan Aschoff maintains a Buy rating on BioRestorative Therapies and raises the price target from $15 to $18.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100